Comparative pharmacogenomics of antiretroviral and cytotoxic treatments

Lancet Oncology

Volumn 7, Issue 1, 2006, Pages 61-68

  Stebbing, Justin ^a   Bower, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DELAVIRDINE; DOCETAXEL; EFAVIRENZ; ERLOTINIB; ETOPOSIDE; GEFITINIB; IMATINIB; INDINAVIR; IRINOTECAN; NATALIZUMAB; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PACLITAXEL; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROFECOXIB; SAQUINAVIR; TENIPOSIDE; UNINDEXED DRUG; VINCA ALKALOID;

BONE MARROW TRANSPLANTATION; CANCER; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG METABOLISM; ENZYME INHIBITION; GENE MUTATION; GENETIC MARKER; GILBERT DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LEUKOPENIA; LIVER TOXICITY; LONG QT SYNDROME; LUNG NON SMALL CELL CANCER; MENTAL DISEASE; MULTIDRUG RESISTANCE; NEUROTOXICITY; NIGHTMARE; PHARMACOGENOMICS; PHYSICIAN; PREDICTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURVIVAL; TREATMENT FAILURE;

ANTI-RETROVIRAL AGENTS; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; DRUG RESISTANCE, MULTIPLE; ENZYME INHIBITORS; HIV INFECTIONS; HUMANS; NEOPLASMS; PHARMACOGENETICS;

EID: 29744459471     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70538-6     Document Type: Review

References (74)

1. TG Roberts Jr BA Chabner Beyond fast track for drug approvals N Engl J Med 351 2004 501-505
2. TJ Lynch DW Bell R Sordella et al Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129-2139
3. WE Evans MV Relling Pharmacogenomics: Translating functional genomics into rational therapeutics Science 286 1999 487-491
4. WE Evans JA Johnson Pharmacogenomics: The inherited basis for interindividual differences in drug response Annu Rev Genomics Hum Genet 2 2001 9-39
5. DA Payne BJ Bryant HIV pharmacogenomics: Closer to personalized therapy? Am J Pharmacogenomics 4 2004 141-150
6. Knight JC Regulatory polymorphisms underlying complex disease traits J Mol Med 83 2005 97-109
7. S Senn Individual response to treatment: Is it a valid assumption? BMJ 329 2004 966-968
8. J Stebbing M Bower What can oncologists learn from HIV? Lancet Oncol 4 2003 438-445
9. M Ratner FDA pharmacogenomics guidance sends clear message to industry Nat Rev Drug Discov 4 2005 359
10. T Dervieux B Meshkin B Neri Pharmacogenetic testing: Proofs of principle and pharmacoeconomic implications Mutat Res 573 2005 180-194
11. S Mallal D Nolan C Witt et al Association between presence of HLA-B 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir Lancet 359 2002 727-732
12. A Fernandez DS Tawfik B Berkhout et al Protein promiscuity: Drug resistance and native functions-HIV-1 case J Biomol Struct Dyn 22 2005 615-624
13. ER Camp J Summy TW Bauer et al Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor Clin Cancer Res 11 2005 397-405
14. RA Smith LA Loeb BD Preston Lethal mutagenesis of HIV Virus Res 107 2005 215-228
15. E Lai C Bowman A Bansal et al Medical applications of haplotype-based SNP maps: Learning to walk before we run Nat Genet 32 2002 353
16. IP Gorlov OY Gorlova CI Amos Predicting the oncogenicity of missense mutations reported in the International Agency for Cancer Research (IARC) mutation database on p53 Hum Mutat 26 2005 446-454
17. Bayer R Oppenheimer GM AIDS doctors, voices from the epidemic, an oral history 2002 Oxford University Press Oxford
18. F Barre-Sinoussi JC Chermann F Rey et al Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) Science 220 1983 868-871
19. DD Loeb R Swanstrom L Everitt et al Complete mutagenesis of the HIV-1 protease Nature 340 1989 397-400
20. GJ Hanna RT D'Aquila Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy Clin Infect Dis 32 2001 774-782
21. J Stebbing B Gazzard DC Douek Where does HIV live? N Engl J Med 350 2004 1872-1880
22. FJ Palella Jr KM Delaney AC Moorman et al Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators N Engl J Med 338 1998 853-860
23. M Miller M Jaskolski JK Rao et al Crystal structure of a retroviral protease proves relationship to aspartic protease family Nature 337 1989 576-579
24. LA Kohlstaedt J Wang JM Friedman et al Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor Science 256 1992 1783-1790
25. J Stebbing BG Gazzard Clinical utility of resistance testing J HIV Ther 7 2002 75-79
26. F Clavel AJ Hance HIV drug resistance N Engl J Med 350 2004 1023-1035
27. BM Rothschild BJ Witzke I Hershkovitz Metastatic cancer in the Jurassic Lancet 354 1999 398
28. US Centers for Disease Control Update on acquired immune deficiency syndrome (AIDS)-United States MMWR Morb Mortal Wkly Rep 31 1982 507-508
29. Shepherd FA Rodrigues Pereira J Ciuleanu T et al Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123-132
30. JG Paez PA Janne JC Lee et al EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy Science 304 2004 1497-1500
31. S Kobayashi TJ Boggon T Dayaram et al EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 2005 786-792
32. BJ Druker S Tamura E Buchdunger et al Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells Nat Med 2 1996 561-566
33. S Blencke A Ullrich H Daub Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors J Biol Chem 278 2003 15435-15440
34. F Baldanti S Paolucci L Dossena G Gerna Assays for determination of HIV resistance to antiviral drugs Curr Drug Metab 5 2004 317-319
35. SA Wegner MR Wallace NE Aronson et al Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: Results of the clinical efficacy of resistance testing trial Clin Infect Dis 38 2004 723-730
36. C Torti E Quiros-Roldan M Regazzi et al A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: The Resistance and Dosage Adapted Regimens (RADAR) study Clin Infect Dis 40 2005 1828-1836
37. J Stebbing M Nelson C Orkin et al A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART) J Antimicrob Chemother 53 2004 501-505
38. V Latham J Stebbing S Mandalia et al Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol J Antimicrob Chemother 56 2005 186-189
39. R Patarca A Isava R Campo et al Human immunodeficiency virus type 1 pharmacogenomics in clinical practice: Relevance of HIV-1 drug resistance testing (part 2) J Environ Pathol Toxicol Oncol 22 2003 235-279
40. R Patarca A Isava R Campo et al Human immunodeficiency virus type 1 pharmacogenomics in clinical practice: Relevance of HIV-1 drug resistance testing (part 1) J Environ Pathol Toxicol Oncol 22 2003 201-234
41. B Laupeze L Amiot B Drenou et al High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival Br J Haematol 116 2002 834-838
42. B van der Holt B Lowenberg AK Burnett et al The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis Blood 106 2005 2646-2654
43. van der Olson DP Scadden DT D'Aquila RT De Pasquale MP The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1) AIDS 16 2002 1743-1747
44. A Saitoh KK Singh CA Powell et al An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children AIDS 19 2005 371-380
45. J Fellay C Marzolini ER Meaden et al Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study Lancet 359 2002 30-36
46. S Rodriguez-Novoa P Barreiro I Jimenez-Nacher et al Pharmacogenetics in HIV therapy AIDS Rev 7 2005 103-112
47. EJ Topol Failing the public health-rofecoxib, Merck, and the FDA N Engl J Med 351 2004 1707-1709
48. LM Berstein EN Imyanitov AJ Kovalevskij et al CYP17 and CYP19 genetic polymorphisms in endometrial cancer: Association with intratumoral aromatase activity Cancer Lett 207 2004 191-196
49. K Takada M Arefayene Z Desta et al Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis Arthritis Rheum 50 2004 2202-2210
50. J Hirth PB Watkins M Strawderman et al The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance Clin Cancer Res 6 2000 1255-1258
51. C Csajka C Marzolini K Fattinger et al Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection Clin Pharmacol Ther 73 2003 20-30
52. T Lang K Klein J Fischer et al Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver Pharmacogenetics 11 2001 399-415
53. JS Barrett AS Joshi M Chai et al Population pharmacokinetic meta-analysis with efavirenz Int J Clin Pharmacol Ther 40 2002 507-519
54. M Pfister L Labbe JF Lu et al Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir Clin Pharmacol Ther 72 2002 133-141
55. DW Haas HJ Ribaudo RB Kim et al Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study AIDS 18 2004 2391-2400
56. M Rotger S Colombo H Furrer et al Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients Pharmacogenet Genomics 15 2005 1-5
57. S Rodriguez-Novoa P Barreiro A Rendon et al Influence of 516G→T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects Clin Infect Dis 40 2005 1358-1361
58. Y Honda F Ushigome N Koyabu et al Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux Br J Pharmacol 143 2004 856-864
59. SM Hammer KE Squires MD Hughes et al for the AIDS Clinical Trials Group 320 Study Team A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less N Engl J Med 337 1997 725-733
60. M Johnson B Grinsztejn C Rodriguez et al Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures AIDS 19 2005 153-162
61. DS Stein DG Fish JA Bilello et al A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir) AIDS 10 1996 485-492
62. RH Tukey CP Strassburg Human UDP-glucuronosyltransferases: Metabolism, expression, and disease Annu Rev Pharmacol Toxicol 40 2000 581-616
63. CP Strassburg N Nguyen MP Manns RH Tukey Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium Mol Pharmacol 54 1998 647-654
64. SD Zucker X Qin SD Rouster et al Mechanism of indinavir-induced hyperbilirubinemia Proc Natl Acad Sci USA 98 2001 12671-12676
65. F Lentz A Tran E Rey et al Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: Clinical implications Am J Pharmacogenomics 5 2005 21-33
66. S Marsh HL McLeod Pharmacogenetics of irinotecan toxicity Pharmacogenomics 5 2004 835-843
67. Y Ando H Saka M Ando et al Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis Cancer Res 60 2000 6921-6926
68. L Iyer S Das L Janisch et al UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity Pharmacogenomics J 2 2002 43-47
69. GJ Peters CH Smorenburg CJ Van Groeningen Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach J Chemother 16 suppl 4 2004 25-30
70. W Lee AC Lockhart RB Kim ML Rothenberg Cancer pharmacogenomics: Powerful tools in cancer chemotherapy and drug development Oncologist 10 2005 104-111
71. M Bower N McCall-Peat N Ryan et al Protease inhibitors potentiate chemotherapy-induced neutropenia Blood 104 2004 2943-2946
72. M Bower T Powles J Stebbing C Thirlwell Potential antiretroviral drug interactions with cyclophosphamide, doxorubicin, and etoposide J Clin Oncol 23 2005 1328-1329
73. S Little The impact of FDA guidance on pharmacogenomic data submissions on drug development IDrugs 8 2005 648-650
74. FDA issues pharmacogenomics data submission guidance Expert Rev Mol Diagn 5 2005 275-277